Telix Pharmaceuticals Limited

Contributing Author

Recent Articles by Telix Pharmaceuticals Limited

Apr-30	TLX101-Px (Pixlumi) MAA Accepted in Europe TLX +5.47% GlobeNewswire
Apr-29	OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer TLX GlobeNewswire
Apr-27	Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next-Generation Portfolio Approach TLX GlobeNewswire
Apr-21	ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026 TLX GlobeNewswire
Apr-14	Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma TLX GlobeNewswire
Apr-13	Telix and Regeneron Announce Strategic Radiopharma Collaboration TLX +6.64% GlobeNewswire
Apr-09	FDA Accepts NDA for TLX101-Px (Pixclara) TLX +7.55% TLX GlobeNewswire
Apr-08	Telix Strengthens Board with Additional Director Appointments TLX GlobeNewswire
Apr-06	Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement TLX +5.94% TLX GlobeNewswire
Apr-01	Telix Appoints David Gill as Non-Executive Director TLX GlobeNewswire
Mar-15	Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara) Brain Cancer Imaging Candidate TLX GlobeNewswire
Mar-09	ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives TLX +5.47% TLX GlobeNewswire
Mar-01	Investor Education Webinar TLX GlobeNewswire
Feb-27	Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging TLX GlobeNewswire
Feb-20	Telix to Participate in Oppenheimer and TD Cowen Conferences TLX +14.61% GlobeNewswire
Feb-19	FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment TLX +14.61% GlobeNewswire
Feb-17	Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging TLX GlobeNewswire
Feb-03	Telix Full Year Results 2025 Investor Webcast Notification TLX GlobeNewswire
Jan-20	Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch TLX GlobeNewswire
Jan-16	First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study TLX GlobeNewswire
Jan-08	Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference TLX GlobeNewswire
Dec-21	Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions TLX GlobeNewswire
Dec-10	Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration TLX GlobeNewswire
Nov-19	ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses TLX GlobeNewswire
Nov-05	Telix to Participate in UBS and Jefferies Global Healthcare Conferences TLX GlobeNewswire
Oct-23	TLX250-CDx (Zircaix) Included in Leading International Guidelines for Renal Imaging TLX GlobeNewswire
Oct-22	Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain TLX GlobeNewswire
Oct-14	Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded TLX +5.24% GlobeNewswire
Sep-23	CMS Grants Transitional Pass-Through Status for Gozellix TLX +8.76% GlobeNewswire
Sep-09	Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis TLX GlobeNewswire
Aug-26	Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference TLX GlobeNewswire
Aug-20	Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth TLX +10.21% GlobeNewswire
Jul-29	Telix H1 2025 Results: Investor Webcast Notification TLX GlobeNewswire
Jul-22	Telix Reports $204M Revenue, Up 63% YOY TLX GlobeNewswire
Jul-09	Gozellix Receives Permanent HCPCS Code TLX +7.84% GlobeNewswire
Jun-23	Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT TLX GlobeNewswire
Jun-20	Telix Precision Medicine Announces AlFluor Radiochemistry Platform TLX GlobeNewswire
Jun-19	Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025 TLX GlobeNewswire
Jun-11	Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S. TLX GlobeNewswire
Jun-03	Telix Investor Day in New York City on June 11, 2025: Presenting KOLs TLX GlobeNewswire
May-22	Telix to Host Investor Day in New York City on June 11, 2025 TLX GlobeNewswire
May-07	Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy TLX GlobeNewswire

Telix Pharmaceuticals Limited

Recent Articles by Telix Pharmaceuticals Limited

Upgrade your Finviz experience